Eli Lilly and Co
LLY
1,287.73
+47.39
+3.82%
Eli Lilly and Co
US · LLY
#17 by market cap
Listed 1970
1,287.73
+47.39
+3.82%
Live - 5344 symbols - heartbeat 150s ago
· 2026-10-20 15:40
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 13 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 79.30% -0.05pp
- Institutions
- 5,307 -13
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund61.63%
Public Company9.49%
Private Company2.88%
Government Pension Fund1.87%
Sovereign Wealth Fund1.37%
Hedge Fund0.92%
Family Office/Trust0.40%
Insurance Company0.26%
Corporate Pension Plan0.20%
Other20.98%
Top holders as of 2026-06-30
BlackRock
7.58% · 67.54M sh
Vanguard Capital Management, LLC
6.52% · 58.12M sh
The PNC Financial Services Group, Inc.
5.74% · 51.12M sh
Capital Research
4.82% · 42.97M sh
State Street Global Advisors
4.06% · 36.22M sh
FMR
2.91% · 25.97M sh
Other
71.28%
Vanguard Portfolio Management, LLC
2.34% · 20.86M sh
Geode Capital Management, LLC
2.28% · 20.31M sh
T. Rowe Price Group, Inc.
1.57% · 13.96M sh
Norges Bank Investment Management
1.29% · 11.47M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 37 buys · 13 sells
| Name | Role | Stake |
|---|---|---|
| David Ricks | Chairperson & CEO | 0.09% |
| Daniel Skovronsky | EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology | 0.03% |
| Anne White | EVP & President of Lilly Neuroscience | 0.01% |
| Patrik Jonsson | EVP, Chief Customer Officer, President of Lilly Diabetes & Obesity and President Lilly USA | 0.01% |
| Anat Hakim | General Counsel | 0.01% |
| Edgardo Hernandez | EVP & President of Manufacturing Operations | 0.01% |
| Anat Ashkenazi | Chief Financial Officer | 0.00% |
| Jacob Van Naarden | EVP, CEO of Loxo Oncology & President of Lilly Oncology | 0.00% |
| Ilya Yuffa | EVP & President of Lilly International | 0.00% |
| Diogo Rau | EVP & Chief Information and Digital Officer | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-20 | Gabrielle Sulzberger | Independent Director | Other Acquisition | +4 | $1,164.89 |
| 2026-09-20 | Jon Erik Fyrwald | Independent Director | Other Acquisition | +8 | $1,164.89 |
| 2026-09-20 | Ralph Alvarez | Independent Director | Other Acquisition | +10 | $1,164.89 |
| 2026-09-20 | Juan Luciano | Lead Independent Director | Other Acquisition | +13 | $1,164.89 |
| 2026-09-08 | Melissa Seymour | Executive Vice President of Global Quality | Other Disposition | -29 | -- |
| 2026-09-01 | Eric Dozier | Executive Vice President | Other Disposition | -216 | -- |
| 2026-09-01 | Edgardo Hernandez | Executive VP & President of Manufacturing Operations | Other Disposition | -13 | -- |
| 2026-08-16 | Gabrielle Sulzberger | Independent Director | Other Acquisition | +4 | $1,183.16 |
| 2026-08-16 | Jon Erik Fyrwald | Independent Director | Other Acquisition | +8 | $1,183.16 |
| 2026-08-16 | Ralph Alvarez | Independent Director | Other Acquisition | +10 | $1,183.16 |
| 2026-08-16 | Juan Luciano | Lead Independent Director | Other Acquisition | +13 | $1,183.16 |
| 2026-08-16 | Patrik Jonsson | Executive VP & President of Lilly International | Automatic Disposition | -6,500 | $1,175.10 |
| 2026-08-09 | Donald Zakrowski | Senior VP of Finance & Chief Accounting Officer | Automatic Disposition | -2,000 | $1,185.01 |
| 2026-08-06 | Anat Hakim | General Counsel | Automatic Disposition | -5,000 | $1,190.00 |
| 2026-07-31 | Melissa Seymour | Executive Vice President of Global Quality | Derivative Exercise and Sale | -438 | $1,148.84 |
| 2026-07-31 | Melissa Seymour | Executive Vice President of Global Quality | Derivative Exercise and Retained | +542 | -- |
| 2026-07-19 | Gabrielle Sulzberger | Independent Director | Other Acquisition | +4 | $1,146.90 |
| 2026-07-19 | Jon Erik Fyrwald | Independent Director | Other Acquisition | +8 | $1,146.90 |
| 2026-07-19 | Ralph Alvarez | Independent Director | Other Acquisition | +10 | $1,146.90 |
| 2026-07-19 | Juan Luciano | Lead Independent Director | Other Acquisition | +13 | $1,146.90 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-20 15:40:08 · For reference only, not investment advice and not tailored to your situation.
the GLP-1 demand curve still doesn’t look like it’s topping, manufacturing capacity is the actual bottleneck here not demand, which is a good problem to have.